A carregar...
CCR5 Antagonism Impacts Vaccination Response and Immune Profile in HIV-1 Infection
Maraviroc (MVC) is the first licensed antiretroviral therapeutic agent to target a host cell surface molecule, and successful HIV-1 entry blockade by this C-C chemokine receptor type 5 (CCR5)-antagonist potentiates immunomodulation. We hypothesized that MVC intensification impacts immunization respo...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
ScholarOne
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3510292/ https://ncbi.nlm.nih.gov/pubmed/22875102 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2119/molmed.2012.00206 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|